Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to -$552000.0.

  • Kyntra Bio's Change in Receivables fell 10251.82% to -$552000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.8 million, marking a year-over-year decrease of 8020.22%. This contributed to the annual value of $6.7 million for FY2024, which is 29624.24% up from last year.
  • Per Kyntra Bio's latest filing, its Change in Receivables stood at -$552000.0 for Q3 2025, which was down 10251.82% from -$159000.0 recorded in Q2 2025.
  • In the past 5 years, Kyntra Bio's Change in Receivables ranged from a high of $26.5 million in Q1 2022 and a low of -$30.6 million during Q2 2024
  • Its 5-year average for Change in Receivables is -$1.1 million, with a median of -$175000.0 in 2022.
  • Per our database at Business Quant, Kyntra Bio's Change in Receivables surged by 208211.08% in 2022 and then crashed by 1116628.57% in 2023.
  • Over the past 5 years, Kyntra Bio's Change in Receivables (Quarter) stood at -$19.0 million in 2021, then soared by 99.08% to -$175000.0 in 2022, then plummeted by 11166.29% to -$19.7 million in 2023, then skyrocketed by 53.23% to -$9.2 million in 2024, then surged by 94.01% to -$552000.0 in 2025.
  • Its last three reported values are -$552000.0 in Q3 2025, -$159000.0 for Q2 2025, and $3.2 million during Q1 2025.